| Dr Alan Robertson Williams Ii, MD | |
|
10180 Se Sunnyside Road, Emergency Department, Clackamas, OR 97015 | |
| (503) 652-2880 | |
| Not Available |
| Full Name | Dr Alan Robertson Williams Ii |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 10180 Se Sunnyside Road, Clackamas, Oregon |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174700215 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | MD158945 (Oregon) | Primary |
| Entity Name | Providence Health & Services Oregon |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093976243 PECOS PAC ID: 3476450560 Enrollment ID: O20031217000186 |
News Archive
National Dentex Corporation, one of the largest owner/operators of dental laboratories in North America, announced that earlier today its shareholders adopted and approved the Agreement and Plan of Merger among GDC Holdings, Inc., a Delaware corporation, Royal Acquisition Corp., a Delaware corporation and an indirect wholly owned subsidiary of Parent and a direct wholly owned subsidiary of GeoDigm Corporation, a Minnesota corporation and National Dentex.
A new pilot study compared the use of human breast milk to formula in children less than 5 years of age who underwent bone marrow transplant (BMT), measuring the levels of inflammatory and pro-inflammatory biomarkers in the stool and blood to assess inflammatory injury to the intestinal microbiome.
Can-Fite BioPharma, a biotechnology company traded on the Tel Aviv Stock Exchange, an Israeli Biopharmaceutical company, announced today the initiation of preparatory work for a Phase III trial with CF101 in Psoriasis. This is based on the successful conclusion of a Phase II dose-response clinical study with CF101 to treat patients with moderate to severe Psoriasis; the study successfully met its primary objective of efficacy and safety
Women who used an injectable contraceptive called DMPA were more likely to acquire HIV than women using a similar product called NET-EN, according to a secondary analysis of data from a large HIV prevention trial called VOICE, researchers from the National Institutes of Health-funded Microbicide Trials Network reported today at the 21st Conference on Retroviruses and Opportunistic Infections in Boston.
RI International CEO and President David Covington announced the launch of the CrisisTech360 app today, providing 24/7/365 real-time visibility of crisis bed availability and program data.
› Verified 5 days ago
| Entity Name | Providence Health & Services Oregon |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952482275 PECOS PAC ID: 3072415652 Enrollment ID: O20040123000519 |
News Archive
National Dentex Corporation, one of the largest owner/operators of dental laboratories in North America, announced that earlier today its shareholders adopted and approved the Agreement and Plan of Merger among GDC Holdings, Inc., a Delaware corporation, Royal Acquisition Corp., a Delaware corporation and an indirect wholly owned subsidiary of Parent and a direct wholly owned subsidiary of GeoDigm Corporation, a Minnesota corporation and National Dentex.
A new pilot study compared the use of human breast milk to formula in children less than 5 years of age who underwent bone marrow transplant (BMT), measuring the levels of inflammatory and pro-inflammatory biomarkers in the stool and blood to assess inflammatory injury to the intestinal microbiome.
Can-Fite BioPharma, a biotechnology company traded on the Tel Aviv Stock Exchange, an Israeli Biopharmaceutical company, announced today the initiation of preparatory work for a Phase III trial with CF101 in Psoriasis. This is based on the successful conclusion of a Phase II dose-response clinical study with CF101 to treat patients with moderate to severe Psoriasis; the study successfully met its primary objective of efficacy and safety
Women who used an injectable contraceptive called DMPA were more likely to acquire HIV than women using a similar product called NET-EN, according to a secondary analysis of data from a large HIV prevention trial called VOICE, researchers from the National Institutes of Health-funded Microbicide Trials Network reported today at the 21st Conference on Retroviruses and Opportunistic Infections in Boston.
RI International CEO and President David Covington announced the launch of the CrisisTech360 app today, providing 24/7/365 real-time visibility of crisis bed availability and program data.
› Verified 5 days ago
| Entity Name | Northwest Acute Care Specialists Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215983200 PECOS PAC ID: 7012807373 Enrollment ID: O20040318001535 |
News Archive
National Dentex Corporation, one of the largest owner/operators of dental laboratories in North America, announced that earlier today its shareholders adopted and approved the Agreement and Plan of Merger among GDC Holdings, Inc., a Delaware corporation, Royal Acquisition Corp., a Delaware corporation and an indirect wholly owned subsidiary of Parent and a direct wholly owned subsidiary of GeoDigm Corporation, a Minnesota corporation and National Dentex.
A new pilot study compared the use of human breast milk to formula in children less than 5 years of age who underwent bone marrow transplant (BMT), measuring the levels of inflammatory and pro-inflammatory biomarkers in the stool and blood to assess inflammatory injury to the intestinal microbiome.
Can-Fite BioPharma, a biotechnology company traded on the Tel Aviv Stock Exchange, an Israeli Biopharmaceutical company, announced today the initiation of preparatory work for a Phase III trial with CF101 in Psoriasis. This is based on the successful conclusion of a Phase II dose-response clinical study with CF101 to treat patients with moderate to severe Psoriasis; the study successfully met its primary objective of efficacy and safety
Women who used an injectable contraceptive called DMPA were more likely to acquire HIV than women using a similar product called NET-EN, according to a secondary analysis of data from a large HIV prevention trial called VOICE, researchers from the National Institutes of Health-funded Microbicide Trials Network reported today at the 21st Conference on Retroviruses and Opportunistic Infections in Boston.
RI International CEO and President David Covington announced the launch of the CrisisTech360 app today, providing 24/7/365 real-time visibility of crisis bed availability and program data.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Alan Robertson Williams Ii, MD 10180 Se Sunnyside Road, Emergency Department, Clackamas, OR 97015 Ph: (503) 652-2880 | Dr Alan Robertson Williams Ii, MD 10180 Se Sunnyside Road, Emergency Department, Clackamas, OR 97015 Ph: (503) 652-2880 |
News Archive
National Dentex Corporation, one of the largest owner/operators of dental laboratories in North America, announced that earlier today its shareholders adopted and approved the Agreement and Plan of Merger among GDC Holdings, Inc., a Delaware corporation, Royal Acquisition Corp., a Delaware corporation and an indirect wholly owned subsidiary of Parent and a direct wholly owned subsidiary of GeoDigm Corporation, a Minnesota corporation and National Dentex.
A new pilot study compared the use of human breast milk to formula in children less than 5 years of age who underwent bone marrow transplant (BMT), measuring the levels of inflammatory and pro-inflammatory biomarkers in the stool and blood to assess inflammatory injury to the intestinal microbiome.
Can-Fite BioPharma, a biotechnology company traded on the Tel Aviv Stock Exchange, an Israeli Biopharmaceutical company, announced today the initiation of preparatory work for a Phase III trial with CF101 in Psoriasis. This is based on the successful conclusion of a Phase II dose-response clinical study with CF101 to treat patients with moderate to severe Psoriasis; the study successfully met its primary objective of efficacy and safety
Women who used an injectable contraceptive called DMPA were more likely to acquire HIV than women using a similar product called NET-EN, according to a secondary analysis of data from a large HIV prevention trial called VOICE, researchers from the National Institutes of Health-funded Microbicide Trials Network reported today at the 21st Conference on Retroviruses and Opportunistic Infections in Boston.
RI International CEO and President David Covington announced the launch of the CrisisTech360 app today, providing 24/7/365 real-time visibility of crisis bed availability and program data.
› Verified 5 days ago
Megan Lea Kelly, Emergency Medicine Medicare: Medicare Enrolled Practice Location: 10180 Se Sunnyside Rd, Kaiser Sunnyside Medical Center, Clackamas, OR 97015 Phone: 503-652-2880 | |
Dr. Nicholas Markham Leonard, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 10180 Se Sunnyside Rd, Clackamas, OR 97015 Phone: 503-652-2880 | |
Dr. Alexander Marsh, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 10180 Se Sunnyside Rd, Kaiser Permanente, Clackamas, OR 97015 Phone: 503-571-8488 | |
James Edward Wood, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 10180 Se Sunnyside Rd, Clackamas, OR 97015 Phone: 503-652-2880 | |
Pamela Marie Johnson, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 10180 Se Sunnyside Rd, Clackamas, OR 97015 Phone: 503-652-2880 | |
John Mullen, Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 10180 Se Sunnyside Rd, Clackamas, OR 97015 Phone: 503-652-2880 | |
Cameron D Klug, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 10180 Se Sunnyside Rd, Clackamas, OR 97015 Phone: 503-571-2000 |